Product details

By continuing to use our site you consent to the use of cookies as described in our privacy policy unless you have disabled them.
You can change your cookie settings at any time but parts of our site will not function correctly without them.
Published by: International Institute for Management Development (IMD)
Originally published in: 2022
Version: 09.03.2022
Revision date: 28-Mar-2022
Length: 19 pages
Data source: Published sources

Abstract

By 2021, Zentiva relied on an internationally diversified network of manufacturing sites, ensuring the production and supply of medicines to millions of people in Europe and beyond. Employing more than 2,300 employees in its wholly owned sites, primarily in Eastern Europe, Zentiva produced medicines that were sold in more than 40 countries. Against the backdrop of changes in the pharma industry - particularly in Europe and in the leading generics market players, which were focused on gaining scale to reduce manufacturing and distribution costs - Zentiva had bold ambitions to become a leading generics and over-the-counter (OTC) manufacturer in Europe by 2025. How could Zentiva derive the benefits of the transformational trends that were impacting pharma players around the world? In view of the changes characterizing the European landscape, would an almost exclusive focus on Eastern Europe be the optimal international growth strategy for the company going forward?

Time period

The events covered by this case took place in 2019-2022.

Geographical setting

Region:
World/global
Country:
Czechia

Featured company

Zentiva
Employees:
1001-5000
Turnover:
USD 869 million
Industry:
Pharmaceuticals

About

Abstract

By 2021, Zentiva relied on an internationally diversified network of manufacturing sites, ensuring the production and supply of medicines to millions of people in Europe and beyond. Employing more than 2,300 employees in its wholly owned sites, primarily in Eastern Europe, Zentiva produced medicines that were sold in more than 40 countries. Against the backdrop of changes in the pharma industry - particularly in Europe and in the leading generics market players, which were focused on gaining scale to reduce manufacturing and distribution costs - Zentiva had bold ambitions to become a leading generics and over-the-counter (OTC) manufacturer in Europe by 2025. How could Zentiva derive the benefits of the transformational trends that were impacting pharma players around the world? In view of the changes characterizing the European landscape, would an almost exclusive focus on Eastern Europe be the optimal international growth strategy for the company going forward?

Settings

Time period

The events covered by this case took place in 2019-2022.

Geographical setting

Region:
World/global
Country:
Czechia

Featured company

Zentiva
Employees:
1001-5000
Turnover:
USD 869 million
Industry:
Pharmaceuticals

Related